Drug intelligence / Profile preview

gemcitabine + docetaxel + BIO-11006

Development stage: Unknown
Lead developer: BioMarck Pharmaceuticals
Modality: Peptides, Small Molecules
Administration: Intravenous, Inhalation

Overview

This is a combination therapy consisting of two established chemotherapeutic agents (gemcitabine and docetaxel) and an investigational peptide (BIO-11006). BIO-11006 is a 10-amino acid peptide that inhibits the myristoylated alanine rich protein kinase C substrate (MARCKS) protein. It prevents MARCKS-mediated signaling, thereby inhibiting tumor cell proliferation, migration, metastasis and survival. Additionally, BIO-11006 reduces mucin granule release and mucus overproduction in the lungs. The combination leverages the cytotoxic effects of gemcitabine and docetaxel with the unique mechanism of BIO-11006 to potentially enhance anti-tumor activity.

Targets

DNA polymerase familyTUBB (Tubulin (alpha and beta subunits))MARCKS (Myristoylated alanine-rich protein kinase C substrate)

Beyond the preview

Go deeper on gemcitabine + docetaxel + BIO-11006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + docetaxel + BIO-11006.

Explore the full profile